Table 3.

EQ-5D values over the double-blind treatment and open-label extension phases of Study 305 for patients starting on rimegepant vs. placebo

Week	Rimegepant/rimegepant OLE			Placebo/rimegepant OLE
	n	EQ-5D mean	EQ-5D SE	n	EQ-5D mean	EQ-5D SE
0	348	0.61	0.01	347	0.60	0.01
12	334	0.72	0.01	330	0.69	0.01
24	283	0.76	0.01	282	0.77	0.01
64	210	0.79	0.01	223	0.79	0.01

OLE open-label extension, SE standard error